Core Viewpoint - 九州通医药集团股份有限公司's wholly-owned subsidiary, Hubei Jiuzhou Industrial Park Operation Management Co., Ltd., has successfully completed the restructuring investment in Aoyuan Meigu Technology Co., Ltd., with the restructuring plan approved and executed as of December 29, 2025 [4][10]. Group 1: Restructuring Investment Overview - On April 23, 2025, 九州通's subsidiary signed a restructuring investment agreement with Aoyuan Meigu and its temporary administrator, committing to invest CNY 673.2 million for 360 million shares post-restructuring [2][5]. - A supplementary agreement was signed on September 24, 2025, adjusting the investment plan, with the number of shares to be acquired increased to 435,930,312 shares for a total investment of CNY 706.207 million [6]. Group 2: Court Proceedings and Restructuring Plan - On November 14, 2025, the Xiangyang Intermediate People's Court accepted Aoyuan Meigu's restructuring application and appointed a management team [3][7]. - The court approved the restructuring plan on December 16, 2025, leading to the termination of the restructuring process [4][11]. - The restructuring process was officially concluded on December 29, 2025, with all obligations under the restructuring plan fulfilled [8][9]. Group 3: Impact on Company Operations and Financials - The restructuring investment aligns with the company's long-term strategic development, enhancing its core competitiveness and enabling collaboration in the beauty and health sector [10]. - The completion of the restructuring is not expected to have a significant short-term impact on the company's financial performance, and there are no adverse effects on the interests of the company and its shareholders [11].

Core Viewpoint - The "beautiful economy" is thriving in Lishui's Liandu District, with significant developments in the beauty and health industry, including partnerships with major beauty brands and impressive industrial output figures [1][4]. Group 1: Industry Development - Liandu District has signed cooperation agreements with beauty giants Proya and Oushiman, positioning itself as a new hub for the beauty and health industry [4]. - The health industry in Liandu has seen a total industrial output value of 9.837 billion yuan from January to November this year, with expectations to exceed 10.88 billion yuan by 2024 [1][5]. - The district has attracted over 100 upstream and downstream enterprises in the beauty and health industry, forming a collaborative industrial structure led by companies like Naies and Mingye Technology [5]. Group 2: Strategic Initiatives - The local government has implemented several strategic plans, including the "Three-Year Action Plan for the Development of Traditional Chinese Medicine and Health Industry" and the "Development Plan for the Beautiful Health Industry" [7]. - Liandu is focusing on six main sectors: ecological beauty, fashion medical aesthetics, oral healthcare, modern traditional medicine, health tea and coffee, and pet products [7]. - The establishment of innovation centers and industry funds totaling 1 billion yuan aims to enhance project attraction and optimize the beauty and health industry chain [7][8]. Group 3: Future Goals - By 2030, the Liandu District aims to achieve an industrial output value of over 20 billion yuan in the beauty and health sector and cultivate nationally influential innovative enterprises [9]. - The district plans to build the "China Lishui Beautiful Health Port" as a central initiative to drive the development of beauty, health, and emotional economy sectors [9].

Core Viewpoint - 九州通医药集团股份有限公司's wholly-owned subsidiary, Hubei Jiuzhou Industrial Park Operation Management Co., Ltd., has participated in the restructuring investment of Aoyuan Meigu Technology Co., Ltd., which has received court approval for its restructuring plan [2][3][4]. Group 1: Restructuring Investment Overview - On April 23, 2025, 九州通's subsidiary signed a restructuring investment agreement with Aoyuan Meigu and its temporary administrator, planning to invest CNY 673.2 million to acquire 360 million shares post-restructuring [2][4]. - On September 24, 2025, a supplementary agreement was signed to adjust the restructuring investment plan, increasing the number of shares to be acquired to 435,930,312, with a total investment of CNY 706.2 million [5]. Group 2: Court Approval of Restructuring Plan - On December 16, 2025, the Xiangyang Intermediate People's Court approved Aoyuan Meigu's restructuring plan, allowing the company to proceed with the execution of the plan and terminating the restructuring process [6][8]. - The court's decision confirmed that the restructuring plan met all legal requirements and was approved by the relevant creditor groups [6][7]. Group 3: Impact on Company Operations and Financials - The restructuring investment aligns with the company's long-term strategic development, enhancing its core competitiveness and enabling deeper collaboration with Aoyuan Meigu in the health and beauty sector [7]. - The execution of the restructuring plan will determine the specific implementation of the investment, with no significant short-term impact on the company's operating performance anticipated [8].

Core Viewpoint - 九州通医药集团股份有限公司's wholly-owned subsidiary, 湖北九州产业园区运营管理有限公司, has signed a restructuring investment agreement with 奥园美谷科技股份有限公司, which has been accepted by the court for restructuring [2][3][4] Group 1: Restructuring Investment Overview - On April 23, 2025, 九州通's subsidiary signed a restructuring investment agreement to invest 673,200,000.00 yuan for 360,000,000 shares of 奥园美谷 post-restructuring [2][4] - On September 24, 2025, a supplementary agreement was signed, adjusting the investment to 706,207,105.44 yuan for 435,930,312 shares, with part of the shares used for debt settlement [5] Group 2: Court Acceptance of Restructuring - On November 14, 2025, the court accepted the restructuring application for 奥园美谷, confirming its inability to pay debts but recognizing its restructuring value [3][6][7] - The court appointed a liquidation team to manage 奥园美谷 during the restructuring process [7][8] Group 3: Impact on Company Operations - The restructuring investment aligns with 九州通's long-term strategic development, enhancing its core competitiveness in the health and wellness sector [8] - Successful restructuring could lead to expanded collaboration in supply chain integration and product development, further strengthening the company's market position [8]